Retatrutide
10mg — 10mg vial
Batch-tested quality with pricing built around repeat research orders.
Research Use Only. This product is intended for research and laboratory use only. Not for human consumption. Not a dietary supplement. No therapeutic claims are made or implied. By purchasing, you confirm this product is for legitimate research purposes.
Product Details
Triple agonist peptide targeting GLP-1, GIP, and glucagon receptors simultaneously. Developed by Eli Lilly (LY3437943), currently in Phase 3 clinical trials for obesity. Represents the next generation beyond dual agonists like tirzepatide, with the glucagon receptor component as the distinguishing feature.
GLP-1 receptor agonism reduces appetite and slows gastric emptying (same pathway as semaglutide). GIP receptor agonism enhances metabolic effects through adipose tissue metabolism and insulin sensitivity. Glucagon receptor agonism increases energy expenditure and promotes hepatic fat oxidation, with the combined GLP-1/GIP agonism offsetting potential glycaemic effects. Phase 2 data showed dose-dependent body weight reduction up to 24.2% at 48 weeks.
Research applications include metabolic pathway studies, body weight and composition research, hepatic fat metabolism, insulin sensitivity research, incretin biology, and comparative studies with mono- and dual-agonists. The triple agonist approach represents largely uncharted territory in metabolic research.
Storage Instructions
- Store lyophilised powder at -20°C for long-term stability
- Reconstituted solution: 2–8°C, use within 2–4 weeks
- Protect from light and moisture
- Shipped with cold packs for temperature stability
Specifications
>98% (HPLC)
Lyophilised powder
10mg
10mg vial